Predicting Progression of STEC-HUS: Use of Shiga Toxin Subtype and Routine Laboratory Screening.

This article focuses on identifying Shiga toxin-producing Escherichia coli (STEC) toxin profiles and clinical factors associated with the progression to hemolytic uremic syndrome (HUS) in children to inform evidence-based screening guidelines. In a retrospective study of 1,071 children under 18 with STEC-positive stool, the highest risk of HUS was linked to E. coli O157 strains producing Shiga toxin 2 (stx2), either alone or with stx1, and non-O157 strains producing stx2; conversely, non-O157 strains producing only stx1 carried negligible HUS risk. Clinical predictors of HUS included age under 5 years, vomiting, dehydration, and abnormal blood counts and chemistry, while abnormal urinalysis and elevated blood pressure were not independently associated. The authors recommend that laboratories report specific stx results to aid clinicians in risk stratification and suggest targeted laboratory monitoring primarily for children with stx2-positive STEC, emphasizing anticipatory guidance and hydration to prevent HUS progression.